2616821-91-9
2616821-91-9 structure
- Name: PERK-IN-5
- Chemical Name: PERK-IN-5
- CAS Number: 2616821-91-9
- Molecular Formula: C25H26F2N4O3
- Molecular Weight: 468.50
- Create Date: 2022-05-25 11:48:44
- Modify Date: 2024-01-14 23:00:38
-
PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC50s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model[1].
| Name | PERK-IN-5 |
|---|
| Description | PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC50s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 2 nM (PERK), 9 nM (p-eIF2α)[1] |
| In Vitro | PERK-IN-5 (compound 28) (10-48 µM) is relatively stable in both human and dog hepatocytes and is characterized with long half-lives[1]. |
| In Vivo | PERK-IN-5 (3-100 mg/kg; p.o.; 0.25-24 hours) has robust pharmacokinetics in CD1 mice, with Cmax of 3353 ng/mL, AUC0-last of 5153 h*ng/mL, and bioavailability of 70%[1]. PERK-IN-5 (3 or 10 mg/kg; p.o.; twice daily, for 28 days) has statistically significant tumor growth inhibition[1]. Animal Model: Female CD1 mice[1] (Pharmacokinetics) Dosage: 3, 10, 30 and 100 mg/kg Administration: p.o.; 0.25-24 hours Result: Showed robust pharmacokinetics with Cmax of 3353 ng/mL, AUC0-last of 5153 h*ng/mL, and bioavailability of 70%. Animal Model: BALB/c nude female mice (inoculated subcutaneously with 786-O tumor cells)[1] Dosage: 3 or 10 mg/kg Administration: p.o.; twice daily, for 28 days Result: Showed statistically significant tumor growth inhibition. |
| References |
| Molecular Formula | C25H26F2N4O3 |
|---|---|
| Molecular Weight | 468.50 |